# US 2013/0156693 A1 · Anti-tat226 antibodies and immunoconjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156693 A1
- Document ID: US20130156693A1
- Status: Published application
- Kind: A1
- Application number: 13/450,326
- Filed: 2012-04-18
- Published: 2013-06-20
- Earliest claimed: 2006-03-17
- Assignees: Genentech, Inc.
- Inventors: Wei-Ching Liang; Chie Sakanaka; Yan Wu
- Web page: https://patentgrep.com/patent/US20130156693A1

## CPC

- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/005: {constructed by phage libraries}
- C07K 16/30: from tumour cells
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.

## Claims

### Claim 1

A method of treating a cell proliferative disorder comprising administering to an individual an effective amount of an immunoconjugate comprising an antibody that binds to TAT226, or antigen-binding fragment thereof, wherein the antibody comprises: a heavy chain variable domain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:4, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:5, and a CDR-H3 comprising an amino acid sequence selected from SEQ ID NO:6-10; a light chain variable domain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:12, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and a CDR-L3 comprising an amino acid sequence selected from SEQ ID NO:14-18, covalently attached to a cytotoxic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CDR-H3 comprises the amino acid sequence of SEQ ID NO:9, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO:17.

### Claim 3 (depends on 1)

The method of claim 1, wherein CDR-H3 comprises the amino acid sequence of SEQ ID NO:10, and the CDR-L3 comprises the amino acid sequence of SEQ ID NO:18.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antibody or antigen-binding fragment thereof further comprises at least one framework selected from a VH subgroup III consensus framework and a VL subgroup I consensus framework.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence selected from SEQ ID NO:21-25 and a light chain variable domain comprising an amino acid sequence selected from SEQ ID NO:26-31.

### Claim 6 (depends on 5)

The method of claim 5, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:24, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:29.

### Claim 7 (depends on 5)

The method of claim 5, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:25, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:30.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein said antibody or antigen-binding fragment thereof is monoclonal.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein said antigen-binding fragment is selected from the group consisting of Fab, Fab′-SH, Fv, scFv, and (Fab1)2 fragments.

### Claim 10 (depends on 8)

The method of claim 8, wherein said antibody or antigen-binding fragment thereof is humanized.

### Claim 11 (depends on 8)

The method of claim 8, wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, an antibiotic, a radioactive isotope, and a nucleolytic enzyme.

### Claim 12 (depends on 9)

The method of claim 9, wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, an antibiotic, a radioactive isotope, and a nucleolytic enzyme.

### Claim 13 (depends on 10)

The method of claim 10, wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, an antibiotic, a radioactive isotope, and a nucleolytic enzyme.

### Claim 14 (depends on 10)

The method of claim 10, wherein the cell proliferative disorder is selected from ovarian cancer, uterine cancer, brain tumor, and Wilms' tumor.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cell proliferative disorder is associated with increased expression of TAT226 on the surface of a cell.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7)

A method of inhibiting cell proliferation comprising exposing a cell to the immunoconjugate of any of claims 1 to 7 under conditions permissive for binding of the immunoconjugate to TAT226.

### Claim 17 (depends on 16)

The method of claim 16, wherein said antibody or antigen-binding fragment thereof is monoclonal.

### Claim 18 (depends on 17)

The method of claim 17, wherein said antigen-binding fragment is selected from the group consisting of Fab, Fab′-SH, Fv, scFv, and (Fab1)2 fragments.

### Claim 19 (depends on 17)

The method of claim 17, wherein said antibody or antigen-binding fragment thereof is humanized.

### Claim 20 (depends on 16)

The method of claim 16, wherein the cell is a tumor cell.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor cell is an ovarian tumor cell, a uterine tumor cell, a brain tumor cell, or a Wilms' tumor cell.

### Claim 22 (depends on 19)

The method of claim 19, wherein the cell is a tumor cell.

### Claim 23 (depends on 22)

The method of claim 22, wherein the tumor cell is an ovarian tumor cell, a uterine tumor cell, a brain tumor cell, or a Wilms' tumor cell.

### Claim 24 (depends on 16)

The method of claim 16, wherein the cell is a xenograft.

### Claim 25 (depends on 16)

The method of claim 16, wherein the exposing takes place in vitro.

### Claim 26 (depends on 16)

The method of claim 16, wherein the exposing takes place in vivo.
